Pharmaceuticals - The Times Of Central Asia

Viewing results 1 - 6 of 37

Pharmaceuticals

EBRD Provides €20 Million Loan to Expand Uzbekistan’s Pharmaceutical Production

Uzbekistan is taking further steps to strengthen its pharmaceutical industry and healthcare system through new investment and sector reforms aimed at reducing reliance on imported medical products. The European Bank for Reconstruction and Development (EBRD) has announced a loan of up to €20 million to its long-term client Samarkand England Eco-Medical (SEEM) and its sister company, Bayan Medical. Both companies produce intravenous solutions, including sodium chloride, glucose, and amino acid infusions, as well as generic and specialized medicines in tablet and capsule form. The financing will support the installation of new production lines at SEEM, enabling the company to expand manufacturing of in-glass intravenous solutions, antibiotics, syrups and suspensions, medical-grade water, nasal sprays, suppositories, and ointments. Part of the funds will also be allocated to modernizing Bayan Medical’s facilities, including energy-efficiency upgrades and the installation of a blow-fill-seal ampoule production line and other specialized equipment. The companies are also expected to restructure their balance sheets as part of the project. The investment comes at a time when approximately 75% of medical goods used in Uzbekistan are imported. Expanding domestic production capacity is intended to promote localization, strengthen supply security, and align manufacturing standards with international requirements. The project also includes social and workforce components. Bayan Medical plans to introduce internship opportunities for university graduates, expand professional training programs for employees, and create new jobs, including positions accessible to people with disabilities. To date, the EBRD has invested nearly $6.9 billion (€5.8 billion) in Uzbekistan across 205 projects, the majority of which have supported private sector development. Uzbekistan has been the largest recipient of EBRD funding in Central Asia for six consecutive years, reflecting sustained economic reforms and investor engagement. Healthcare indicators point to broader structural progress. According to the 2024 Health Care Index published by CEOWORLD magazine, Uzbekistan ranks first in Central Asia and 64th globally, with a score of 36.26. Kazakhstan ranks 78th, and Turkmenistan 95th. Data from the World Health Organization and the World Bank indicate that Uzbekistan’s Universal Health Coverage service index rose from the mid-50s in 2000 to the mid-70s by 2021, suggesting expanded access to essential medical services. Authorities aim to further increase coverage by 2027 while reducing out-of-pocket healthcare spending through strengthened primary care systems and clearer guarantees of publicly funded services.

Pharmaceuticals

Digital Labeling Uncovers Widespread Violations in Kazakhstan’s Pharma Sector

Kazakhstan’s digital drug labeling system, which was due to be fully implemented by the end of 2025, has revealed extensive violations in the distribution and retail of pharmaceuticals. Infractions include the sale of medicines designated for free public distribution, code reuse, and the sale of expired drugs. Introduced in mid-2024, the digital labeling system assigns a unique identifier to every medication package. Kazakhstan is now the only country in Central Asia with a state-controlled, end-to-end digital traceability system covering the entire pharmaceutical supply chain from production and import to pharmacy sales. According to Tanba, the unified national operator for product labeling and traceability, over 708.6 million medicine packages had been labeled as of December 1, 2025. The system now includes nearly all market participants: 19 domestic manufacturers, more than 143 foreign manufacturers, over 300 importers and distributors, approximately 3,900 medical organizations, 4,848 pharmacies, and 3,019 additional supply chain entities. Mandatory labeling applies to all drugs produced after July 1, 2024, and sold within the country. The unique codes allow authorities to trace each medicine’s journey from factory to pharmacy or medical facility, enhancing procurement forecasting and minimizing counterfeit risks. The system automatically detects irregularities in real time. Recent analysis uncovered that some private pharmacies were selling medications purchased with public funds that were meant to be distributed free of charge under the state’s guaranteed volume of free medical care. More than 15,000 such packages were reportedly sold. Additionally, authorities identified over 6,500 reused digital codes, registered a total of more than 385,000 times, and more than 750 cases involving the sale of expired medications. The Times of Central Asia previously reported that the government transferred control of the Social Medical Insurance Fund to the Ministry of Finance in January, following revelations of violations within the fund’s operations.

Pharmaceuticals

Uzbekistan’s Pharmaceutical Market in 2025: Rapid Growth, Foreign Investment, and Localization

Uzbekistan’s pharmaceutical sector is experiencing explosive growth in 2025. According to the analytics firm IQVIA, in September 2025, the market volume reached $204.9 million (wholesale) with 83.1 million packages of medicines sold. This is 36.4% higher in value terms and 24.1% higher in volume than a year earlier, indicating a recovery in consumer demand and a robust post-pandemic market rebound. The total annual market volume (MAT, the twelve months to September 2025) is estimated at $2.14 billion, whereas in 2018 it was about $0.888 billion. Thus, the average annual growth rate over 2018–2025 exceeded 13.4%, with acceleration in 2024–2025. As a result, the country’s pharma market has entered a phase of accelerated development, laying the foundation for further expansion in 2026. Market Structure: Price Segments, Import Dependence, and Prescription Shift to premium segments. The structure of pharmaceutical consumption in Uzbekistan is shifting towards more expensive medications. The share of the cheapest drugs (priced up to $1 per package) is shrinking, whereas the $1–5 and $5–10 segments are growing. At the same time, the niche of drugs priced above $10 is strengthening, reflecting a shift of part of consumer demand toward branded original medicines and complex therapies. This trend indicates qualitative market development: whereas previously inexpensive generics dominated, now an increasing share of revenue comes from innovative and imported products. Imports and local production. Despite localization efforts, the market remains import-dependent – around 90% of sales by value are generated by foreign drugs, with a slight trend toward imports further expanding their share. As of MAT/09/2025, imported medicines have raised their value share from 87% in 2018 to 89%. Nonetheless, in volume terms, the share of local manufacturers has inched up from 40% to 41.2% thanks to the production of affordable generics. Local companies are increasing their presence in the low-price segment by competing on cost. The government is encouraging localization of production, offering incentives (for example, tax and customs benefits in pharmaceutical free economic zones) and reserving 20% of state procurements for domestic companies’ products. These measures have already led a number of foreign companies to begin setting up manufacturing in Uzbekistan. Market Leaders: Companies and Brands Uzbekistan’s pharmaceutical market is highly fragmented – the combined share of even the largest players is relatively small. According to IQVIA for MAT/09/2025, the top three companies by sales value are Slovenia’s KRKA, Turkey’s World Medicine, and Ukraine’s Farmak. These companies together control about 9.9% of the market, which indicates intense competition and a market crowded with numerous brands and manufacturers. Notably, the top ten manufacturers have collectively increased their share since 2018 from 24% to 27%. Among local manufacturers, the Uzbek company Nika Pharm stands out with roughly a 2.5% share, rising from 32nd position in 2018 to 7th in 2025 with a +40.4% increase in sales (in value terms). Nika Pharm has become the most dynamic player in the domestic market and the only local manufacturer in the top ten. Competition at the individual brand level is also intense, with the...

Pharmaceuticals

French Pharma Giant Sanofi to Localize Production in Kazakhstan

French pharmaceutical company Sanofi, one of the world’s largest drugmakers, will localize the production of medical products in Kazakhstan. The agreement was reached following negotiations in Paris between Kazakh health Ministry officials and Sanofi representatives. Sanofi ranked tenth globally by revenue in 2024, earning $44.46 billion, according to Fierce Pharma. “During the discussions, issues related to current joint projects with Kazakhstan in the field of pharmaceuticals, the supply and production of medicines, as well as the development and implementation of innovative medical technologies were touched upon,” the ministry said in a statement. Talks also addressed broader cooperation with the French Development Agency (AFD) and Expertise France, which have been active in Kazakhstan’s healthcare sector. AFD, which opened a representative office in Astana in April, has already provided a €945,000 grant to improve medical infrastructure planning and management. Together with its subsidiary Proparco, the agency also financed a €90 million loan for the construction of a 630-bed hospital in Kokshetau. Beyond healthcare, as previously reported by The Times of Central Asia, the AFD is supporting environmental initiatives in Kazakhstan, including a joint project with France to preserve Lake Balkhash.

Pharmaceuticals

Uzbekistan’s Pharma Pivot: Strategic Gains or Growing Dependence on China

Since 2016, Uzbekistan has steadily deepened its partnership with China across multiple sectors. Energy, infrastructure, agriculture, and the digital economy have long been the pillars of this cooperation. Yet recent discussions showed that the pharmaceutical sector will be another critical area for cooperation in the long term. Much like renewable energy and critical minerals, the pharmaceutical sector is now viewed in Tashkent as a strategic domain where Chinese expertise and investment could accelerate development and add value to the domestic economy. The Compelling Logic of Partnership China's strength lies in its ability to produce high-quality, affordable medicines and distribute them globally at scale. For Uzbekistan - whose growing population and rising demand for advanced healthcare have placed pressure on its system - this makes China a natural partner. At present, the Uzbek pharmaceutical market remains heavily import-dependent: by the end of 2024, imported drugs accounted for 87% of retail sales in monetary terms and 63% in physical volume. This reliance not only exposes vulnerabilities but also highlights the untapped potential for local production. Recognizing this, Tashkent has moved to create favorable conditions for investment. The country has established specialized pharmaceutical Special Economic Zones (SEZ) such as Parkent-Pharm and Andijan-Pharm. These SEZs offer investors an attractive package of incentives, from exemptions on customs duties and VAT for raw materials and equipment, to a 20% preference in government procurement for local products. Such regulatory incentives, combined with a growing domestic market, have already begun to draw interest from Chinese pharmaceutical firms. Strategic Priorities Recently, Uzbekistan has signed a series of memorandums of understanding with Chinese firms such as Zhendong Health Industry, Guojo Medical Technology, and Langtian Pharma Group, signaling a stronger bilateral focus on the pharmaceutical sector. These agreements align closely with Uzbekistan’s strategic goal of building a robust domestic pharmaceutical industry with an emphasis on access to capital and technology, localization, and human capital development. One of Uzbekistan’s key priorities is securing access to capital and expertise. Without investment and collaboration with experienced companies, the state cannot establish modern laboratories and production facilities. In this regard, the Uzbek company, Ozwell, has signed an MoU with Zhendong Health Industry Group to jointly implement a modern pharmaceutical laboratory. The partnership involves a total investment of $9.5 million, with $4.5 million allocated toward creating a world-class laboratory facility and $5 million designated for establishing and scaling up a production complex. This agreement reflects Tashkent’s desire to tap into Chinese technical knowledge and experience, while simultaneously building domestic capacity and developing local talent in the long term. Another critical priority is the localization of drug production. By reducing dependency on imports, Uzbekistan is aiming to strengthen supply chain resilience, meet domestic demand, and create new opportunities for regional exports. In this regard, the MoU established with Langtian Pharma Group and Guojo Medical Technology is designed to investigate opportunities for domestic production while promoting technological collaboration and knowledge transfer within the pharmaceutical industry. The final priority is the development of human capital. In this regard, Uzbekistan...

Pharmaceutical Business

Tajikistan’s Pharmaceutical Sector Remains Heavily Dependent on Imports

Despite possessing vast reserves of medicinal plants, Tajikistan's pharmaceutical industry remains heavily reliant on imports. Experts are increasingly questioning why the sector has been reduced to a basic "buy-and-sell" model and what is hindering the use of the country’s natural resources. Abundant Resources, Limited Output Tajikistan is home to more than 3,500 species of medicinal plants, including licorice, mint, valerian, chamomile, motherwort, and even rare saffron. However, this natural wealth has not translated into pharmaceutical independence. In the past two years alone, Tajikistan has imported roughly $84 million worth of medicines. Currently, 67 pharmaceutical companies are registered in the country, producing around 600 types of drugs. Still, imported pharmaceuticals dominate the market. According to industry observers, the sector has evolved into a retail-focused trade, rather than a hub for research-based production. During the Soviet era, pharmaceuticals in Tajikistan were closely integrated with scientific institutions. Research institutes flourished, pharmacies compounded custom medications, and both training and quality control were rigorous. Following the collapse of the USSR, this infrastructure disintegrated. The responsible state committee was dissolved, and a previously regulated system was replaced by an unstructured market. Today, training programs are often accelerated, pharmacists’ qualifications are inconsistent, and the emphasis has shifted from treatment to sales. A Pharmacy That Heals Amid this decline, one notable exception is found in the city of Isfara, where a phytotherapy department has been established at the local hospital. Spearheaded by pharmacist Abubakr Faiziev, the department operates out of a restored facility where locally gathered herbs are used to produce traditional infusions and decoctions. Faiziev personally collects about half of the ingredients. “It is important to me that the pharmacy heals, not just sells,” he said. According to Faiziev, approximately 80% of patients return for follow-up treatment, often bypassing conventional doctors due to the perceived effectiveness of herbal therapies, a sentiment echoed even among members of the local elite. A Science in Decline Faiziev laments the erosion of scientific ambition in the country. "People now ask for business plans and guaranteed profits instead of pursuing knowledge. But science doesn’t work that way," he said. Research, he noted, has become sporadic and often relies on outdated data, with little interest from private companies in investing in innovation. Young professionals, too, are increasingly opting for commercial routes. “They prefer to open pharmacies for fast income rather than engage in research,” he explained. “There are many pharmacists now. But we must transform quantity into quality. Without passion for the profession, one cannot become a skilled expert.” The State’s Role and Untapped Potential President Emomali Rahmon has repeatedly stressed the need to develop the domestic pharmaceutical industry and better utilize Tajikistan’s natural resources. Ongoing reforms include updates to medical university curricula, the opening of laboratories, and the training of technologists and quality control specialists. Yet, experts argue that without a comprehensive, systematic strategy and active engagement from the private sector, these measures are insufficient. Faiziev advocates for the creation of a pharmaceutical technology park and the development of both the domestic...